Kelowna, British Columbia – September 7, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces strategic additions to its patent…
Lexaria is technology for improved delivery of bioactive compounds.
CSE:LXX; OTCQX:LXRP
Welcome to Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i.e. fat soluble) and difficult for the human gastrointestinal system to efficiently and effectively absorb. DehydraTECH™ greatly improves the body’s ability to absorb these substances so their benefits can be received more quickly and pleasantly.
Lexaria has multiple patents issued or pending in over 40 countries around the world.
About DehydraTECH™
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Avoids first-pass liver metabolism
Initial testing indirectly evidences DehydraTECH™ may deliver ingested molecules through the lymphatic system instead of being subject to immediate liver exposure, potentially mitigating unwanted side effects.
Increases bio-absorption
Bio-absorption increases by 5 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria Bioscience Corp’s disruptive new technology DehydraTECH™ can be licensed to improve existing products or create revolutionary new ones.
DehydraTECH™ Commercial Applications
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Latest News
Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results
Lexaria’s technology delivered 195% more nicotine across the blood-brain-barrier conceptually allowing for smaller micro doses in accordance with developing FDA policies. Lexaria’s formulation was 4x faster at reaching its peak…
Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing Delivery Measured Within Minutes
Nicotine, in an edible form, delivered to blood plasma within minutes after dosing. Statistically significant positive in vivo results (n=40; two groups of 20 animals). 90.2% greater delivery by the 10-minute mark of the…